PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 9 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Flavonoid fractions and cucurbitacins (23,24-dihydrocucurbitacin B and cucurbitacin R) inhibited mouse paw and ear oedema induced by carrageenan, phospholipase A2, serotonin, and TPA [PMID:19041703, PMID:15124085].
Oral administration of 23,24-dihydrocucurbitacin B (1 mg/kg) in Lewis rats reduced swelling, bone and tissue damage, and modified cell infiltration [PMID:16443215].
Dihydrocucurbitacin B inhibited inflammatory reactions induced by oxazolone, dinitrofluorobenzene, and sheep red blood cells in mice [PMID:17562851].
Certain nor-cucurbitacin glucosides (cayaponosides B and C2) exhibited inhibitory effects on Epstein-Barr virus activation and anti-tumor-promoting effects in mouse skin tumor models [PMID:7742799].
Evidence summary
PubMed sources
- 1.PMID: 19041703 (2009) — Anti-inflammatory activity of flavonoids from Cayaponia tayuya roots. · Journal of ethnopharmacology
- 2.PMID: 16443215 (2006) — Dihydrocucurbitacin B, isolated from Cayaponia tayuya, reduces damage in adjuvant-induced arthritis. · European journal of pharmacology
- 3.PMID: 15124085 (2004) — Anti-inflammatory activity of two cucurbitacins isolated from Cayaponia tayuya roots. · Planta medica
- 4.PMID: 1464123 (1992) — Structures of cayaponosides A, B, C and D, glucosides of new nor-cucurbitacins in the roots of Cayaponia tayuya. · Chemical & pharmaceutical bulletin
- 5.PMID: 17562851 (2007) — Dihydrocucurbitacin B inhibits delayed type hypersensitivity reactions by suppressing lymphocyte proliferation.